[November 30, 2017] |
|
Agendia: New Data at the San Antonio Breast Cancer Symposium Demonstrate the Value of MammaPrint® and BluePrint® Across Breast Cancer Patient Populations
Agendia, Inc., a world leader in personalized medicine and molecular
cancer diagnostics, announces the presentation of extensive new data at
the upcoming 2017 San Antonio Breast Cancer Symposium (SABCS),
highlighting the value of its MammaPrint® 70-Gene Breast
Cancer Risk-of-Recurrence Test and BluePrint® Breast Cancer
Molecular Subtyping Test. A total of eleven posters and discussions are
being presented at SABCS, which will take place at the Henry B. Gonzales
Convention Center in San Antonio, Texas from December 5-9, 2017.
The posters and presentations feature important new data from the I-SPY
2 trial (Neoadjuvant and Personalized Adaptive Novel Agents to Treat
Breast Cancer) and the IMPACt trial (Measuring the Impact of MammaPrint
on Adjuvant and Neoadjuvant Treatment in Breast Cancer Patients: A
Prospective Registry) as well as cost-effectiveness data and performance
data across patient populations of different ages, and those affected by
obesity and other metabolic factors.
A highlight will be the oral presentation on Thursday, December 7 which
will show the first long-term survival results from the I-SPY 2 trial
for patients pre-selected by MammaPrint.
Dr. William Audeh, Chief Medical Officer at Agendia, said:
"The breadth and depth of the new data being presented at SABCS clearly
demonstrates the broad application of MammaPrint and BluePrint in
helping to guide breast cancer treatment decisions in a wide range of
patient populations. In addition, it underscores the important role that
MammaPrint can take in clinical trials like I-SPY 2. Physicians and
their patients want to feel confident that they are using the test that
is backed with the highest level of clinical evidence and the most
comprehensive data, and MammaPrint can provide this reassurance."
Abstracts are available to view on the SABCS
website. For more information please visit the Agendia team at booth
601.
Wednesday, December 6
-
Poster P1-02-05: The effect of obesity and metabolic factors
on genomic assays for risk of recurrence; Hall 1, 17:00 - 19:00
CST Poster Session 1.
-
Poster P1-07-08: Young age and the risk of disease
recurrence as assessed by the 70-gene signature - an analysis from the
EORTC10041/BIG 03-04 MINDACT trial; Hall 1, 17:00 - 19:00
CST Poster Session 1.
Thursday, December 7
-
Poster P2-09-19: Genomic biomarker for resistance to
Palbociclib in the NeoPalAna Trial; >Hall 1, 07:00 - 09:00 CST
Poster Session 2.
-
Poster P2-09-08: Analysis of biomarkers for response and
resistance to the AKT inhibitor MK-2206 in the neoadjuvant I-SPY 2
trial for stage II-III high-risk breast cancer; Hall 1, 07:00 -
09:00 CST Poster Session 2.
-
Oral Session GS3-08: Pathological complete response
predicts event-free and distant disease-free survival in the I-SPY2
TRIAL; Hall 3, 11:15, 09:30 - 11:30 CST General Session 3.
-
Poster Discussion PD6-08: Analysis of immune infiltrates
(assessed via multiplex fluorescence immunohistochemistry) and immune
gene expression signatures as predictors of response to the checkpoint
inhibitor; Stars at Night Ballroom 3 & 4, 17:00 - 19:00 CST Immuno
Oncology.
-
Poster Discussion PD6-14: Analysis of DNA repair deficiency
biomarkers as predictors of response to the PD1 inhibitor
pembrolizumab: Results from the neoadjuvant I-SPY 2 TRIAL for Stage
II-III high-risk breast cancer; Stars at Night Ballroom 3 & 4,
17:00 - 19:00 CST Immuno Oncology.
Friday, December 8
-
Poster P4-12-01: MammaPrint is cost-effective compared to
clinical risk assessment in early stage breast cancer; Hall
1, 07:00 - 09:00 Poster Session 4.
Saturday, December 9
-
Poster P6-13-04: IMPACt Trial: MammaPrint and BluePrint
molecular subtyping guide treatment decisions in Breast Cancer;
Hall 1, 07:00 - 09:00 Poster Session 6.
-
Poster P6-13-06: A community based study utilizing the
70-gene signature (MammaPrint) for treatment decisions in elderly
patients; Hall 1, 07:00 - 09:00 Poster Session 6.
-
Poster P6-15-07: Pathologic Complete Response (pCR) in
Locally Advanced Triple Negative (TN) and HER2+ (HER2+) Breast Cancer
(BC) Treated with Anthracycline-Free Neoadjuvant Therapies and
Associations with Gene Expression (GE) Patterns, Tandem Repeats (TR),
and Intratumoral Cellular Compositions; Hall 1, 07:00 -
09:00 Poster Session 6.
- Ends -
About MammaPrint® MammaPrint is an in
vitro diagnostic test, performed in a central laboratory, using the
gene expression profile of breast cancer tissue samples to assess a
patients' risk for distant metastasis. MammaPrint is cleared by the US
FDA and carries the CE Mark, enabling the use of the test in the
European Union. MammaPrint is indicated for use by physicians as a
prognostic marker only, along with other clinical-pathological factors.
The test is not intended to determine the outcome of disease, nor to
suggest or infer an individual patient's response to therapy.
About Agendia Agendia is a privately held, leading molecular
diagnostics company that develops and markets genomic diagnostic
products, which help support physicians with their complex treatment
decisions. Agendia's breast cancer tests were developed using an
unbiased gene selection by analyzing the complete human genome. Our
offerings include the MammaPrint® 70-Gene Breast Cancer
Risk-of-Recurrence Test, and the BluePrint® Molecular
Subtyping Test that provide deeper insight leading to more clinically
actionable breast cancer biology.
In addition, Agendia has a pipeline of other genomic products in
development. The company collaborates with pharmaceutical companies,
leading cancer centers and academic groups to develop companion
diagnostic tests in the area of oncology.
For more information on Agendia or the MammaPrint and BluePrint tests,
you can visit Agendia's patient site at www.KnowYourBreastCancer.com
or the corporate site at www.agendia.com.
Follow Agendia, Inc. on Facebook,
Twitter,
or LinkedIn
to keep up-to-date with the latest news.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171130005599/en/
[ Back To TMCnet.com's Homepage ]
|